Example: Heart Attack

Search clinical trials for: Mecamylamine

Total 30 results

NCT03914677

Recruiting

Mecamylamine for Autonomic Dysreflexia Prophylaxis

Conditions: Spinal Cord Injuries
NCT00773812

Completed

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

Conditions: Autistic Disorder; Pervasive Developmental Disorder
NCT00563797

Completed

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Conditions: Alcohol Dependence; Depression
NCT00593879

Completed

Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder

Conditions: Major Depressive Disorder
NCT00342563

Completed

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Conditions: Alcoholism
NCT00536692

Completed

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Conditions: Diabetic Macular Edema
NCT00455650

Completed

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

Conditions: Cognition in Schizophrenia
NCT04756232

Not yet recruiting

Cholinergic Mechanisms of Attention in Aging

Conditions: Subjective Cognitive Decline
NCT00319319

Completed

Nicotinic Receptor Augmentation of SSRI Antidepressants

Conditions: Depressive Disorder
NCT03244488

Completed

Mental Ability Challenge Study in Adults With and Without HIV

Conditions: HIV-1-infection; Aging, Premature; Cognitive Impairment; Memory Impairment; HIV-Associated Cognitive Motor Complex
NCT03408574

Recruiting

The Nicotinic Cholinergic System and Cognitive Aging

Conditions: Healthy Aging
NCT00414206

Terminated

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Conditions: Macular Degeneration
NCT00607750

Completed

Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

Conditions: Age-Related Macular Degeneration
NCT01223404

Completed

Nicotinic Modulation of the Default Network

Conditions: Magnetic Resonance Imaging; Cognition; Nicotine; Mecamylamine
NCT00018187

Completed

Combinations of Pharmacologic Smoking Cessation Treatments

Conditions: Smoking
NCT04129060

Recruiting

Cholinergic Health After Menopause (CHAMP)

Conditions: Postmenopausal Symptoms; Aging; Alzheimer Disease
NCT00018161

Completed

Treatment to Quit Smoking

Conditions: Smoking
NCT00692445

Completed

TC-5214 as add-on the Treatment of Major Depressive Disorder

Conditions: Major Depressive Disorder; Depression
NCT01458899

Completed

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

Conditions: Healthy Subjects
NCT01240967

Completed

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Conditions: Healthy Volunteers; Patients; Pharmacokinetics; Renal Impairment
NCT01175564

Completed

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

Conditions: Healthy
NCT01157078

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Conditions: Major Depressive Disorder; Depression
NCT01152554

Completed

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Conditions: Major Depressive Disorder; MDD; Depression
NCT01180400

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Conditions: Major Depressive Disorder; Depression
NCT01145768

Completed

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Conditions: Healthy